Sangamo Therapeutics Inc. (SGMO)

13.88
0.12 0.86
NASDAQ : Health Technology
Prev Close 14.00
Open 13.97
Day Low/High 13.55 / 14.13
52 Wk Low/High 11.30 / 27.50
Volume 1.36M
Avg Volume 2.23M
Exchange NASDAQ
Shares Outstanding 101.67M
Market Cap 1.40B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of January 2021 Options Trading For Sangamo Therapeutics (SGMO)

First Week Of January 2021 Options Trading For Sangamo Therapeutics (SGMO)

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Despite $5.1 billion deal for Costa, I'm not slurping any KO up.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

Salesforce Remains a 'Go to' Name for Big Cap Momentum Players

Salesforce Remains a 'Go to' Name for Big Cap Momentum Players

I expect CRM to regain its footing quickly and challenge highs again soon.

HPE: Surpassing Expectations, Raising Guidance Incrementally

HPE: Surpassing Expectations, Raising Guidance Incrementally

If estimates continue to come up there will be institutional interest in the stock.

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Apple in particular is helping the bullish cause.

Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment

First Week Of SGMO September 21st Options Trading

First Week Of SGMO September 21st Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I

Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I

RICHMOND, Calif., July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics To Acquire TxCell

Sangamo Therapeutics To Acquire TxCell

The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development

Sangamo Therapeutics Announces Technology Leadership Changes

Sangamo Therapeutics Announces Technology Leadership Changes

RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Appoints Karen Smith To Its Board Of Directors

Sangamo Therapeutics Appoints Karen Smith To Its Board Of Directors

RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Interesting SGMO Put And Call Options For July 20th

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

TheStreet Quant Rating: D+ (Sell)